Ben is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
32 articles by Ben Fidler
-
Gilead puts $375M into Arcus in latest push to broaden cancer business
May 27, 2020 -
Merck makes COVID-19 drug plans clear with flurry of deals
May 26, 2020 -
Sunovion crowds a new group of Parkinson's drugs, with uncertain sales prospects
May 22, 2020 -
US secures supply of AstraZeneca, Oxford coronavirus vaccine, pledging more than $1B
May 21, 2020 -
AstraZeneca, Merck race past Clovis as PARPs break into prostate cancer
May 20, 2020 -
Bristol Myers, trailing Merck in lung cancer, finally wins FDA OK for immunotherapy combo
May 18, 2020 -
Moderna delivers first human data for a coronavirus vaccine
May 18, 2020 -
Safety questions linger as Pfizer preps Duchenne gene therapy for final test
May 15, 2020 -
Allogene gives first look at an 'off the shelf' cell therapy for lymphoma
May 13, 2020 -
Surprise setback for Bristol, Bluebird as FDA rejects cell therapy application
May 13, 2020 -
A closer look at the race to develop antibody drugs for COVID-19
May 12, 2020 -
Akebia, chasing FibroGen, nears FDA review with new anemia pill data
May 5, 2020 -
Moderna, with government cash, taps Lonza to make 1 billion doses of COVID-19 vaccine
May 1, 2020 -
AstraZeneca, racing past rivals, throws its weight behind Oxford's COVID-19 vaccine
April 30, 2020 -
Thrive, chasing Grail with a cancer blood test, finds tumors in seemingly healthy women
April 28, 2020 -
Another step for PARPs as AstraZeneca, Merck drug extends lives in prostate cancer
April 24, 2020 -
Why $120M for Affinivax may reflect a new view of vaccine makers
April 23, 2020 -
Seattle Genetics wins another speedy approval as FDA clears breast cancer drug
April 17, 2020 -
NIH spearheads broad partnership with drugmakers, regulators to speed COVID-19 therapies
April 17, 2020 -
Moderna's coronavirus vaccine plan may be possible, but a lot has to go in its favor
April 14, 2020 -
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
April 8, 2020 -
FDA's new Keytruda review is a step for genetic medicine, immunotherapy
April 7, 2020 -
Gilead to lean on Second Genome's microbiome work in $38M research pact
April 6, 2020 -
Fate inks $100M J&J pact for 'off-the-shelf' cancer cell therapies
April 3, 2020 -
Drugmakers await reckoning as doctors, patients make tough choices during pandemic
April 1, 2020